Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.66 |
| ▸ | ADA | P00813 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2920192-A1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | University College Cardiff Consultants Limited (GB) | 2015-09-23 | — | — | EP | claimed |
| WO-2014076490-A1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2014-05-22 | — | — | WO | claimed |
| EP-3177294-B1 | COMPOSITIONS COMPRISING A PNP INHIBITOR FOR USE IN THE TREATMENT OF THE RELAPSE OF MALIGNANCY FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANT | LAEVOROC IMMUNOLOGY AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| US-20200079814-A1 | Nucleotides comprising an N-[(S)-1-cyclobutoxycarbonyl]phosphoramidate moiety and analogs and application thereof | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190224224-A1 | Guanosine as an Immune Potentiator Mediated through Toll Receptors | NITOR THERAPEUTICS (US) | 2019-07-25 | — | — | US | disclosed |
| US-10278984-B2 | Guanosine as an immune potentiator mediated through toll receptors | NITOR THERAPEUTICS (US) | 2019-05-07 | — | — | US | disclosed |
| EP-3473636-A1 | NUCLEOTIDES CONTAINING AN N-[(S)-1-CYCLOBUTOXYCARBONYL]PHOSPHORAMIDATE FRAGMENT, ANALOGS THEREOF, AND USE THEREOF | Alla Chem, LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10266558-B2 | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof | ALLA CHEM, LLC | 2019-04-23 | — | — | US | disclosed |
| EP-2655392-B1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180099989-A1 | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof | ALLA CHEM, LLC | 2018-04-12 | — | — | US | disclosed |
| US-20180030080-A1 | Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2018-02-01 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2385951-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | University College Cardiff Consultants, Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254856-A1 | MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL | LG ELECTRONICS INC. (KR) | 2011-10-20 | — | — | US | disclosed |
| WO-2011123668-A2 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | ADORA2A 223/4885ADA 24/4885ADORA3 271/4885 |
| US-20180030080-A1 | Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use | HCCS, NTPCR, NSUN2 | ADORA2A 1846/4885ADA 1771/4885ADORA3 609/4885 |
| US-20200079814-A1 | Nucleotides comprising an N-[(S)-1-cyclobutoxycarbonyl]phosphoramidate moiety and analogs and application thereof | NSUN2, PNP, HCCS | ADORA2A 776/4885ADA 657/4885ADORA3 928/4885 |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PPA1, ENPP1, ITPA | ADORA2A 780/4885ADA 329/4885ADORA3 1334/4885 |
| US-20180099989-A1 | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof | TYMS, TYMP, DCTD | ADORA2A 501/4885ADA 19/4885ADORA3 621/4885 |
| US-10266558-B2 | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof | TYMS, TYMP, DCTD | ADORA2A 391/4885ADA 16/4885ADORA3 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.